A Phase 3 interventional study of Eptinezumab and Placebo in Migraine, sponsored by H. Lundbeck A/S. Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 8th largest by enrollment, is the only one that started in 2019, is one of 13 in phase 3, and was the 7th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 485 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 7th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
This will be a parallel group, double-blind, randomized, placebo-controlled study assessing the efficacy of eptinezumab for acute migraine, defined as an active intercurrent migraine occurring in those participants who are candidates for preventive therapy. Participants will be randomized to receive a single dose of eptinezumab or placebo in a 1:1 ratio. The total study duration will be approximately 4 to 12 weeks, including up to an 8-week screening period and 4-week of safety follow-up, with clinic visits occurring on Screening, Day 0 (dosing day), and Week 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following medication, for any indication, within the 24-hour period prior to dosing with study drug:
Use of the following medication, for any indication, in each of the 3 months prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
Drug: Eptinezumab
Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
Drug: Placebo
Injection for IV administration
Injection for IV administration
Time to Headache Pain Freedom
Time to headache pain freedom defined as the time that the participant reported freedom of pain, meaning their headache pain had gone from moderate to severe at baseline to no pain.
Time frame: Up to 48 hours postdose
Time to Absence of Most Bothersome Symptom (MBS)
Time to absence of most bothersome symptom defined as the time that the participant reported absence of MBS (of nausea, photophobia, or phonophobia).
Time frame: Up to 48 hours postdose
Headache Pain Freedom at 2 Hours
Number of participants with freedom from headache pain at 2 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.
Time frame: 2 hours
Absence of MBS at 2 Hours
Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 2 hours postdose are reported.
Time frame: 2 hours
Headache Pain Freedom at 4 Hours
Number of participants with freedom from headache pain at 4 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.
Time frame: 4 hours
Absence of MBS at 4 Hours
Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 4 hours postdose are reported.
Time frame: 4 hours
Use of Rescue Medication Within the First 24 Hours
Rescue medication was defined as any medication to treat migraine or migraine-associated symptoms, which could have been provided to the participant any time after 2 hours post-start of infusion. Use of rescue medication was captured in the eDiary. Number of participants who used rescue medication up to 24 hours postdose are reported.
Time frame: Up to 24 hours postdose
| Milestone | Eptinezumab | Placebo |
|---|---|---|
| Started | 241 | 244 |
| Received at least 1 dose of study drug | 238 | 242 |
| Completed | 235 | 241 |
| Not completed | 6 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Randomized but not treated | 3 | 2 |
Time to headache pain freedom defined as the time that the participant reported freedom of pain, meaning their headache pain had gone from moderate to severe at baseline to no pain.
| hours | Eptinezumab | Placebo |
|---|---|---|
| Time to Headache Pain Freedom | 4.0 (2.5 to 12.0) | 9.0 (3.0 to 48.0) |
Time to absence of most bothersome symptom defined as the time that the participant reported absence of MBS (of nausea, photophobia, or phonophobia).
| hours | Eptinezumab | Placebo |
|---|---|---|
| Time to Absence of Most Bothersome Symptom (MBS) | 2.0 (1.0 to 3.5) | 3.0 (1.5 to 12.0) |
Number of participants with freedom from headache pain at 2 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Headache Pain Freedom at 2 Hours | 56 | 29 |
Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 2 hours postdose are reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Absence of MBS at 2 Hours | 132 | 86 |
Number of participants with freedom from headache pain at 4 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Headache Pain Freedom at 4 Hours | 111 | 64 |
Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 4 hours postdose are reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Absence of MBS at 4 Hours | 155 | 90 |
Rescue medication was defined as any medication to treat migraine or migraine-associated symptoms, which could have been provided to the participant any time after 2 hours post-start of infusion. Use of rescue medication was captured in the eDiary. Number of participants who used rescue medication up to 24 hours postdose are reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Use of Rescue Medication Within the First 24 Hours | 75 | 145 |
Collected over Start of treatment (Day 0) through end of study (Week 4). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eptinezumab | 0/238 (0%) | 0/238 (0%) | 5/238 (2.1%) |
| Placebo | 0/242 (0%) | 0/242 (0%) | 0/242 (0%) |
| Event | Eptinezumab | Placebo |
|---|---|---|
| HypersensitivityImmune system disorders | 5/238 | 0/242 |
Safety population included all participants who received eptinezumab or placebo.
| Age, Continuous(years) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Mean | 44.9 ± 11.99 | 44.1 ± 12.12 | 44.5 ± 12.05 |
| Sex: Female, Male(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Female | 202 | 201 | 403 |
| Male | 36 | 41 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 31 | 60 |
| Not Hispanic or Latino | 209 | 211 | 420 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Race — White | 200 | 213 | 413 |
| Race — Black or African American | 30 | 19 | 49 |
| Race — Asian | 2 | 3 | 5 |
| Race — American Indian or Alaska Native | 2 | 1 | 3 |
| Race — Native Hawaiian or other Pacific Islander | 1 | 1 | 2 |
| Race — Other | 0 | 1 | 1 |
| Race — Multiple | 3 | 4 | 7 |
| Number of Migraine Days/Month(days/month) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Mean | 7.2 ± 2.65 | 7.2 ± 2.56 | 7.2 ± 2.60 |
| Number of Participants With Most Bothersome Symptoms (MBS)(participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Photophobia | 114 | 114 | 228 |
| Nausea | 78 | 79 | 157 |
| Phonophobia | 46 | 47 | 93 |
| Missing | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2019 to primary completion in Jul 2020, 8 months.
Results were first posted in Aug 2021, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 8 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab